Eczema

Phase I/II trials to begin for NF-KB Decoy in eczema

Published in Health and Medicine Week, October 18th, 2004

Corgentech, Inc., (CGTK), a biotechnology company, announced that it plans to initiate a phase I/II clinical trial in the first half of 2005 in eczema with NF-Kappa-B Decoy (NF-KB Decoy), a highly selective and potent inhibitor of immune and inflammatory responses.

"Our lead product candidate, edifoligide (E2F Decoy) is tracking well, and top-line results are expected for our phase III studies in peripheral bypass graft by the end of this year and coronary artery bypass graft in early 2005. We are, therefore, able to expand our focus to bringing our second and third transcription factor decoys to the clinic, thereby continuing to build long-term value for our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry